Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Ascher Svanum, Haya ^a   Zhao, Fangyi ^a   Detke, Holland C ^a   Nyhuis, Allen W ^b   Lawson, Anthony H ^a   Stauffer, Virginia L ^a   Montgomery, William ^c   Witte, Michael M ^b   McDonnell, David P ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING OLANZAPINE; OLANZAPINE; PLACEBO; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; STATISTICS; TIME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 80053174914     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-152     Document Type: Article

References (25)

1. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003, 60:1228-1235. 10.1001/archpsyc.60.12.1228, 14662555.
2. Kapur S, Arenovich T, Agid O, Zipursky RB, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005, 162:939-946. 10.1176/appi.ajp.162.5.939, 15863796.
3. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005, 57:1543-1549. 10.1016/j.biopsych.2005.02.023, 15953491.
4. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Barker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008, 34:1163-1171. 10.1093/schbul/sbm134, 2632496, 18156640.
5. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003, 160:2063-2065. 10.1176/appi.ajp.160.11.2063, 14594760.
6. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008, 102:230-240.
7. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590. 10.1038/npp.2009.164, 3055392, 19890258.
8. Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresposne among patients with schizophrenia. J Clin Psychiatry 2007, 68:353-360.
9. Stauffer V, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res Epub 2010 Dec 18.
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
11. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69:790-799. 10.4088/JCP.v69n0512, 18452346.
12. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
13. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984, 10:388-398.
14. Leucht S, Kissling W, David JM. The PANSS should be rescaled. Schizophr Bull 2010, 36:461-462. 10.1093/schbul/sbq016, 2879684, 20357133.
15. Obermeier M, Mayr A, Schennach-Wolff R, Seemuller F, Moller HJ. Should the PANSS be rescaled?. Schizophren Bull 2010, 36:455-460.
16. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001, 62:757-771. 10.4088/JCP.v62n1003, 11816864.
17. Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res 2009, 113:34-40. 10.1016/j.schres.2009.06.001, 19564097.
18. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006, 67:1114-1123. 10.4088/JCP.v67n0715, 16889456.
19. Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, Green AI. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry 2007, 68:1163-1171. 10.4088/JCP.v68n0801, 17854239.
20. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699. 10.1176/appi.ajp.161.4.692, 15056516.
21. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Miraz M, Vana J. Intermittent vs maintenance medication in schizophrenia. Two-year results. Ach Gen Psychiatry 1991, 48:333-339.
22. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005, 3:21. 10.1186/1741-7015-3-21, 1327673, 16375765.
23. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull 2010, 36:624-632. 10.1093/schbul/sbn120, 2879688, 18849294.
24. Ruberg S, Chen L, Stauffer V, Ascher-Svanum H, Kollack-Walker S, Conley RR, Kane J, Kinon BJ. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2011, 9(11):23.
25. Levine SZ, Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry 2010, 68:86-92. 10.1016/j.biopsych.2010.01.012, 20227681.